Sleep quality, anxiety and depression in advanced lung cancer: patients and caregivers.


Journal

BMJ supportive & palliative care
ISSN: 2045-4368
Titre abrégé: BMJ Support Palliat Care
Pays: England
ID NLM: 101565123

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 15 10 2018
revised: 07 09 2019
accepted: 11 02 2020
pubmed: 8 4 2020
medline: 7 7 2022
entrez: 8 4 2020
Statut: ppublish

Résumé

To investigate the clinical implications of sleep quality, anxiety and depression in patients with advanced lung cancer (LC) and their family caregivers (FCs). A total of 98 patients with advanced LC and their FCs (n=98) were recruited from the Oncology Department in Nanfang Hospital. The Pittsburgh Sleep Quality Index (PSQI), consisting of seven components that evaluate subjective sleep quality, sleep latency, duration of sleep, sleep efficiency, sleep disturbances, sleep medication usage and daytime dysfunction, was used to assess sleep quality. Using the tool of Zung Self-rating Anxiety Scale (SAS) and Zung Self-rating Depression Scale (SDS), we tested the patients' status of anxiety and depression, respectively. The prevalences of poor sleep quality, anxiety and depression in patients were 56.1%, 48.9% and 56.1%, respectively, while those in FCs were 16.3%, 32.6% and 25.5%, respectively. Patients had higher PSQI, SAS and SDS scores than did FCs (p<0.05). Significant correlations were found between the patients' and FCs' scores of PSQI/SAS/SDS (p<0.05). Multivariate Cox regression analyses indicated that sleep disturbances in patients (HR 0.413, 95% CI 0.21 to 0.80, p=0.01) and the global PSQI score of FCs (HR 0.31, 95% CI 0.14 to 0.71, p=0.00) were independent risk factors for patients' first-line progression-free survival (PFS). Moreover, patients' sleep latency (HR 2.329, 95% CI 1.36 to 3.96, p=0.00) and epidermal growth factor receptor mutations (HR 1.953, 95% CI 1.12 to 3.38, p=0.01) were significant prognostic factors for their overall survival (OS). We demonstrated that presence of sleep disturbances in patients with advanced LC and the global PSQI Score of their FCs may be risk predictors for patients' poor first-line PFS. Patients' sleep latency was a potential risk factor for their OS.

Identifiants

pubmed: 32253349
pii: bmjspcare-2018-001684
doi: 10.1136/bmjspcare-2018-001684
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e194-e200

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Yuan He (Y)

Department of Oncology/ Medical Center for Overseas Patients, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China.
Department of Ultrasound and Electrocardiogram, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Li-Yue Sun (LY)

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Kun-Wei Peng (KW)

Department of Oncology/ Medical Center for Overseas Patients, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China.

Man-Jun Luo (MJ)

Department of Oncology/ Medical Center for Overseas Patients, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China.

Ling Deng (L)

Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Tao Tang (T)

Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Chang-Xuan You (CX)

Department of Oncology/ Medical Center for Overseas Patients, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China ycx6026@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH